A modified human α2-macroglobulin derivative that binds tumor necrosis factor-α and interleukin-1β with high affinity in vitro and reverses lipopolysaccharide toxicity in vivo in mice

Laboratory Investigation

Volumn 78, Issue 8, 1998, Pages 939-948

  Webb, Donna J ^a   Gonias, Steven L ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CROHN DISEASE; ENZYME INDUCTION; IMMUNOPATHOGENESIS; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RHEUMATOID ARTHRITIS;

ALPHA-MACROGLOBULINS; ANIMALS; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INTERLEUKIN-1; IODINE RADIOISOTOPES; KINETICS; LIPOPOLYSACCHARIDES; MICE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PROTEIN BINDING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031818035     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Aggarwal BB, Eessalu TE, and Hass PE (1985). Characterization of receptors for human tumour necrosis factor and their regulation by γ-interferon. Nature 318:665-667.
2. Beutler B, Milsark LW, and Cerami AC (1985). Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869-871.
3. 2-macroglobulin on reaction with methylamine or proteolytic enzymes. Biochem J 207:347-356.
4. 2-macroglobulin. Biochemistry 29:4081-4087.
5. 2-macroglobulin as a cytokine binding plasma protein. J Biol Chem 264:5818-5825.
6. Brandtzaeg P (1996). Significance and pathogenesis of septic shock. In: Rietschel ET and Wagner H, editors: Pathology of septic shock. New York: Springer-Verlag, 15-37.
7. Cohen J, Heumann D, and Glauser MP (1995). Do monoclonal antibodies and anticytokines still have a future in infectious diseases? Am J Med 99(Suppl 6A):45S-53S.
8. 2-macroglobulin-cytokine interactions based on affinity of noncovalent association in solution under apparent equilibrium conditions. J Biol Chem 269:1533-1540.
9. Cunha FQ, Assreuy J, Moss DW, Rees D, Leal LMC, Moncada S, Carrier M, O'Donnell CA, and Liew FY (1994). Differential induction of nitric oxide synthase in various organs of the mouse during endotoxaemia: Role of TNF-α and IL-1-β. Immunology 81:211-215.
10. 2-Macroglobulin is a binding protein for basic fibroblast growth factor. J Biol Chem 264:7210-7216.
11. Elliott MJ, Feldmann M, and Maini RN (1995). TNFα blockade in rheumatoid arthritis: Rationale, clinical outcomes and mechanisms of action. Int J Immunopharmacol 17:141-145.
12. Gårdlund B, Sjolin J, Nilsson A, Roll M, Wickerts C-J, and Wretlind B (1995). Plasma levels of cytokines in primary septic shock in humans: Correlation with disease severity. J Infect Dis 172:296-301.
13. 2-macroglobulin: Properties of recombinant C949S variants. FEBS Lett 339:276-280.
14. 2-macroglobulin conformational intermediates obtained by derivatization with cis-dichlorodiammineplatinum (II). J Biol Chem 264:9565-9570.
15. 2-macroglobulin receptor/LRP: A growth regulatory axis. Ann NY Acad Sci 737:273-290.
16. 2-macroglobulin by the antitumor drug cis-dichlorodiammineplatinum (II). J Biol Chem 256:12478-12484.
17. 2-macroglobulin following reaction with methylamine and trypsin. Biochim Biophys Acta 705:306-314.
18. Gormley PE, Bull JM, LeRoy AF, and Cysyk R (1979). Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther 25: 351-357.
19. Heumann D and Glauser MP (1996). Anticytokine strategies for the treatment of septic shock: Relevance of animal models. In: Rietschel ET and Wagner H, editors: Pathology of septic shock. New York: Springer-Verlag, 299-311.
20. 2-macroglobulin complex is a latent form of transforming growth factor β. J Biol Chem 263:1535-1541.
21. 2-macroglobulin. J Biol Chem 256:8134-8139.
22. Keffer J, Probert L, Cazlari H, Georgopoulos S, Kaslaris E, Kioussis D, and Kollias G (1991). Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J 10:4025-4031.
23. 2-macroglobulin conformational intermediates by electron microscopy and image processing. J Biol Chem 267:6347-6352.
24. Neurath MF, Fuss I, Pasparakis M, Alexopoulou L, Haralambous S, zum Büschenfelde K-HM, Strober W, and Kollias G (1997). Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 27:1743-1750.
25. 2-macroglobulin. J Biol Chem 262:14090-14099.
26. Offner F, J Philippe, D Vogelaers, F Colardyn, G Baele, M Baudrihaye, A Vermeulen, and G Leroux-Roels (1990). Serum tumor necrosis factor levels in patients with infectious disease and septic shock. J Lab Clin Med 116:100-105.
27. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, and Dinarello CA (1988). Interleukin-1 induces a shock-like state in rabbits. J Clin Invest 81:1162-1172.
28. 2-macroglobulin: Role in transforming growth factor-β1 clearance. J Biol Chem 266: 22290-22296.
29. Probert L, Akassoglou K, Alexopoulou L, Doun IE, Haralambous SH, Hill S, Kassiotis G, Kontoyiannis D, Pasparakis M, Plows D, and Kollias G (1996). Dissection of the pathologies induced by transmembrane and wild-type tumor necrosis factor in transgenic mice. J Leukocyte Biol 59:518-525.
30. Raetz CRH, Ulevitch RJ, Wright SD, Sibley CH, Ding A, and Nathan CF (1991). Gram-negative endotoxin: An extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J 5:2652-2660.
31. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, Holmes G, Long R, Forbes A, and Kamm MA (1997). Randomized controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 349:521-524.
32. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, and Rutgeerts PJ (1997). A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's Disease. N Engl J Med 337:1029-1035.
33. Thiemermann C, Szabo C, Mitchell JA, and Vane JR (1993). Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. Proc Natl Acad Sci USA 90:267-271.
34. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee TA, Kuo GC, Lowry SF, and Cerami A (1987). Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662-664.
35. 2-macroglobulin gene. J Biol Chem 270:19778-19785.
36. van Deventer SJH (1997). Tumor necrosis factor and Crohn's disease. Gut 40:443-448.
37. van de Loo FAJ, Arntz OJ, Bakker AC, van Lent PLEM, Jacobs MJM, and van den Berg WB (1995a). Role of interleukin 1 in antigen-induced exacerbations of murine arthritis. Am J Pathol 146:239-249.
38. van de Loo FAJ, Joosten LAB, van Lent PLEM, Arntz OJ, and van den Berg WB (1995b). Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Arthritis Rheum 38:164-172.
39. van Lent PLEM, van de Loo FAJ, Holthuysen AEM, van den Beisselaar LAM, and van den Berg WB (1995). Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice. J Rheumatol 22:2250-2258.
40. 2-macroglobulin in an episomal expression system. Biochem J 312:183-190.
41. 2-macroglobulin. J Biol Chem 269:30402-30406.
42. 2-macroglobulin to generate derivatives that bind transforming growth factor-β with increased affinity. FEBS Lett 410:249-253.
43. 2-macroglobulin which is responsible for the binding of transforming growth factor-β (abstract). FASEB J 11:3087.
44. 2-macroglobulin. Biochem J 320:551-555.
45. 2-macroglobulin to a 20-kDa peptide that also contains the bait region. J Biol Chem 273:13339-13346.
46. Webb DJ, Wen J, Lysiak JJ, Umans L, Van Leuven F, and Gonias SL (1996b). Murine α-macroglobulins demonstrate divergent activities as neutralizers of transforming growth factor-β and as inducers of nitric oxide synthesis. J Biol Chem 271:24982-24988.
47. 2-macroglobulin under apparent equilibrium conditions. Biochemistry 33:11270-11277.
48. 2 macroglobulin. Am J Pathol 138:265-272.
49. Wooley PH, Whalen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, and Staite ND (1993). The effect of an interleukin 1 receptor antagonist protein on type II collagen-induced arthritis and antigen induced arthritis in mice. Arthritis Rheum 36:1305-1314.